Peptides / Growth hormone axis

Synthetic analog · 8 amino acids · 1,096.3 Da

Lanreotide

ApprovedNot banned in sport

Lanreotide (Somatuline Depot) is a somatostatin analog approved in the US for acromegaly, some neuroendocrine tumors and carcinoid syndrome, and in EU countries. Studies in people tested it mostly on growth hormone, IGF-1 and tumor growth, and tracked side effects. PepBank shows 532 results on lanreotide from 91 studies in people, and 53 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Somatuline Depot

8 amino acids, from first to lastXCYWKVCT

Evidence level: Large trials in people532 of 585 results come from studies in people, including randomized trials.

Results in people

532

91% of 585 results

Results in animals

2% of 585 results

Results in lab cells

7% of 585 results

From computer models

0% of 585 results

Overview

Lanreotide at a glance

What it is	Synthetic analog, 8 amino acids
Approval	Approved in the US and EU (Somatuline Depot)
In sport	Not listed as banned by WADA
Studies	110 studies with results. 109 of them gave lanreotide, with 585 results. 532 in people10 in animals43 in lab cells
Best study in people	Randomized controlled trial with 309 people (2018)
Clinical trials	85 registered: 8 active or planned, 30 with posted results
Community use	Adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival.

The science

What is lanreotide?

Lanreotide is a cyclic eight-residue somatostatin analog.

Amino acids in one chain

The history of lanreotide

1993
The oldest paper on lanreotide in PepBank is from 1993.
2006June
A registered trial of lanreotide started (NCT00353496).

Lanreotide structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 8 amino acidsFrom the first amino acid to the last

X1CYW+K5VCT

Darker means more water-repelling+ and − show charge in the bodyOutlined: changed amino acid

Structure

Lanreotide is a synthetic analog of 8 amino acids, with a ring, 1 disulfide bond, 2 changed amino acids.

Formula

C₅₄H₆₉N₁₁O₁₀S₂

Molecular weight

1,096.3 g/mol

CAS number

108736-35-2

Target

Somatostatin receptors: agonistEvidence: Official prescribing information, mechanism of action

Development

Highest phase: past the trial stage (see status).

Identifiers

PubChem 6918011, ChEMBL CHEMBL1201185, UNII 0G3DE8943Y, DrugBank DB06791

Full sequence, SMILES and InChIKey

InChIKey
PUDHBTGHUJUUFI-SCTWWAJVSA-N

SMILES
C[C@H]([C@@H](C(=O)N)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)C(C)C)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)N)O

See charge, composition and 3D structure on the Scientific page

The evidence

What lanreotide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people532 of 585 results come from studies in people, including randomized trials.

Growth hormone and growth

118 results · 109 in people · 1 animal · 8 lab

In Chinese patients with acromegaly, autogel was noninferior to prolonged-release lanreotide for IGF-1 SDS in the ITT analysis. BMC endocrine disorders, 2020

Top results

In Chinese patients with acromegaly, autogel was noninferior to prolonged-release lanreotide for IGF-1 SDS in the ITT analysis. (BMC endocrine disorders, 2020)
In rats with aortic allografts, lanreotide reduced locally produced insulin-like growth factor 1. (FASEB journal, 1993)
In cells from a human bronchial carcinoid, lanreotide reduced GHRH secretion. (The Journal of clinical endocrinology and metabolism, 2005)

Cancer

121 results · 103 in people · 2 animal · 16 lab

In patients with enteropancreatic NETs, lanreotide prolonged time without disease progression compared with placebo. The New England journal of medicine, 2014

Top results

In patients with enteropancreatic NETs, lanreotide prolonged time without disease progression compared with placebo. (The New England journal of medicine, 2014)
In advanced liver cancer, five lanreotide-treated patients (24%) had blood AFP decreases of at least 30%. (International journal of oncology, 2000)
In NFPMA patients, lanreotide did not significantly change tumor diameter compared with placebo. (The Lancet regional health. Europe, 2024)

Stomach and gut

49 results · 49 in people

Lanreotide reduced days needing rescue octreotide compared with placebo. Endocrine practice, 2016

Top results

Lanreotide reduced days needing rescue octreotide compared with placebo. (Endocrine practice, 2016)
In adults with postoperative dumping syndrome, total symptom scores fell versus baseline after lanreotide but not after placebo. (United European gastroenterology journal, 2019)
After pancreatic surgery, 24-hour pancreatic output did not decrease significantly with lanreotide compared with placebo. (Digestive and liver disease, 2002)

Blood sugar

16 results · 16 in people

HbA1c did not significantly change from baseline during lanreotide treatment in the overall population. Clinical endocrinology, 2017

Top results

HbA1c did not significantly change from baseline during lanreotide treatment in the overall population. (Clinical endocrinology, 2017)
In healthy men, insulin decreased only 2 h after lanreotide injection compared with the control day. (British journal of clinical pharmacology, 1994)
Mean fasting glucose did not significantly change from baseline during lanreotide treatment in the overall population. (Clinical endocrinology, 2017)

Daily life and fitness

16 results · 16 in people

Quality of life did not change significantly with lanreotide compared with standard care. JAMA, 2018

Top results

Quality of life did not change significantly with lanreotide compared with standard care. (JAMA, 2018)
In patients with hormone-refractory prostate cancer, performance status improved in 40% during lanreotide treatment. (Cancer chemotherapy and pharmacology, 1995)
In functional midgut NET patients receiving lanreotide, 87.5% had a symptomatic response. (Journal of neuroendocrinology, 2022)

Liver

16 results · 16 in people

In patients with polycystic liver, liver volume decreased with lanreotide and increased with placebo. Gastroenterology, 2009

Top results

In patients with polycystic liver, liver volume decreased with lanreotide and increased with placebo. (Gastroenterology, 2009)
In patients with ADPKD and polycystic liver disease, lanreotide reduced liver volume growth by 5.91% versus standard care. (Gastroenterology, 2019)
In patients with ADPKD, lanreotide reduced combined liver and kidney volume growth by 7.18% versus standard care. (Gastroenterology, 2019)

Lanreotide has 908 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 110 lanreotide studies by area Open the Scientific page

Key lanreotide studies

Studies in people come first, then studies in animals and in the lab.

People
Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial
Meijer et al. 2018 · JAMA · 309 people · cited by 100
10 results
People
Lanreotide in metastatic enteropancreatic neuroendocrine tumors
Caplin et al. 2014 · The New England journal of medicine · 204 people · cited by 1,288
6 results
People
Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease
van et al. 2019 · Gastroenterology · 175 people · cited by 53
4 results
People
Lanreotide Autogel 90 mg and lymphorrhea prevention after axillary node dissection in breast cancer: a phase III double blind, randomized, placebo-controlled trial
Gauthier et al. 2012 · European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 145 people · cited by 10
3 results
People
A three-year randomized, double-blind, placebo-controlled study of lanreotide in stage 2/3 autosomal dominant polycystic kidney disease
Joly et al. 2026 · Kidney international · 144 people · cited by 0
8 results

All 110 Lanreotide studies

Lanreotide clinical trials

ClinicalTrials.gov lists 85 trials of lanreotide. 8 are active or planned, and 30 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours

Phase 3completed264 people

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

Phase 3completed198 people

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Phase 3completed128 people

All 49 Lanreotide trials

Status and safety

Is lanreotide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Somatuline Depot). The FDA label for Somatuline Depot says: “Adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Lanreotide side effects and safety

PepBank has 98 safety results from studies of lanreotide. 98 of them come from studies in people.

Safety results from studies (98)

In patients with NETs, injection pain did not differ significantly between lanreotide and octLAR. (JCO oncology practice, 2022)
In patients with enteropancreatic NETs, treatment-related diarrhea occurred in 26% with lanreotide versus 9% with placebo. (The New England journal of medicine, 2014)
In adults with ADPKD, digestive adverse events were more frequent with lanreotide than placebo. (Kidney international, 2026)
In Chinese patients with acromegaly, safety profiles were similar with both lanreotide formulations. (BMC endocrine disorders, 2020)
In adults with postoperative dumping syndrome, adverse event counts did not differ significantly between lanreotide and placebo. (United European gastroenterology journal, 2019)
Hepatic cyst infections occurred only in lanreotide recipients, compared with standard care. (Drug safety, 2017)
In polycystic kidney disease, new gallstones occurred in 15% with lanreotide versus 1% with standard care. (Drugs in R&D, 2021)
In acromegaly with large pituitary tumors, surgical complications were similar after lanreotide pretreatment and direct surgery. (European journal of endocrinology, 2010)
In neuroendocrine tumor patients, both lanreotide formulations were well tolerated, with no safety concerns identified. (Cancer, 2006)
In NFPMA patients, adverse events affected 100% with lanreotide versus 95% with placebo. (The Lancet regional health. Europe, 2024)
Adverse events did not differ between high-dose and high-frequency lanreotide. (The Journal of clinical endocrinology and metabolism, 2017)
In healthy subjects, lanreotide bolus caused more side effects than infusion. (Clinical pharmacology and therapeutics, 2004)
Injection site discomfort occurred more often with lanreotide than with standard care. (JAMA, 2018)
In acromegaly, three patients had digestive complaints with lanreotide but not octreotide. (Clinical endocrinology, 2008)
No treatment-related serious adverse events occurred during intensified lanreotide treatment in progressive NET patients. (European journal of cancer, 2021)
After preoperative lanreotide, 27 patients developed complications. (HPB, 2022)
In SCLC patients receiving lanreotide, treatment-related adverse events occurred in 28%. (Lung cancer, 2019)
Injection site hardening occurred in 28.1% of Japanese NET patients receiving lanreotide. (Investigational new drugs, 2017)
In progressive NETs, 19 patients (63%) experienced treatment-related adverse events with lanreotide. (BMC cancer, 2013)
In active acromegaly, digestive problems were the most common adverse events during lanreotide treatment. (Clinical endocrinology, 2008)
In acromegaly, patients generally tolerated lanreotide well. (Clinical endocrinology, 2000)
In acromegaly, all patients tolerated lanreotide well. (Pituitary, 2010)
In acromegaly, no patient left lanreotide treatment because of adverse events. (Journal of endocrinological investigation, 2009)
Adverse event rates after switching to lanreotide were similar to those during prior placebo, except more diarrhea was considered treatment-related. (Endocrine-related cancer, 2016)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
120 mg every 4 weeks	Human	human	subcutaneous	2.5 years	Randomized trial in people · n = 309	Meijer 2018
120 mg every 28 days	Human	human	Not reported	96 weeks	Randomized trial in people · n = 204	Caplin 2014
120 mg every 4 weeks	Human	human	subcutaneous	120 weeks	Randomized trial in people · n = 175	van 2019
90 mg	Human	human	Not reported	Not reported	Randomized trial in people · n = 145	Gauthier 2012
120 mg monthly	Human	human	injection	three years	Randomized trial in people · n = 144	Joly 2026
Autogel 60/90/120 mg monthly	Human	human	deep subcutaneous injection	32 weeks	Randomized trial in people · n = 128	An 2020
120 mg every 4 weeks	Human	human	Not reported	16 weeks	Randomized trial in people · n = 115	Vinik 2016
30 mg PR	Human	human	intramuscular	Single first injection; outcome assessed within 72 hours	Randomized trial in people · n = 107	Gayral 2009
30 mg every 2 weeks, increased to weekly at week 8 if mean GH >2.5 microg/l	Human	human	intramuscular	4 months	Randomized trial in people · n = 98	Mao 2010
30 mg, one injection	Human	human	Not reported	10 days	Randomized trial in people · n = 80	Mariani 2012
120 mg every 28 days	Human	human	subcutaneous	Up to 1 year or progression	Randomized trial in people · n = 71	Santo 2019
120 mg every 4 weeks	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 64	Fisher 2018
30 mg every two weeks	Human	human	intramuscular	12 weeks	Randomized trial in people · n = 60	Chang 2006
120 mg every 28 days	Human	human	Not reported	24 weeks	Randomized trial in people · n = 54	van 2009
120 mg every 28 days	Human	human	Not reported	until progression or toxicity	Randomized trial in people · n = 53	Lepage 2022
120 mg every 28 days	Human	human	deep subcutaneous injection	72 weeks	Randomized trial in people · n = 44	Boertien 2024
120 mg every 4 weeks	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 40	Timmer 2024
90 mg monthly	Human	human	Not reported	Three monthly injections	Randomized trial in people · n = 24	Wauters 2019
120 mg every 28 days	Human	human	subcutaneous	120 weeks	Randomized trial in people · n = 309	Lantinga 2017
120 mg every 4 weeks	Human	human	deep subcutaneous	96 weeks	Randomized trial in people · n = 204	Buil-Bruna 2016
120 mg every 4 weeks	Human	human	subcutaneous	16 weeks	Randomized trial in people · n = 115	Fisher 2018
120 mg every 28 days	Human	human	Not reported	Not reported	Randomized trial in people · n = 77	Baudin 2024
30 mg every 2 weeks, increased to 30 mg/week at week 8 if GH nadir >2.5 μg/l	Human	human	intramuscular	3 months	Randomized trial in people · n = 49	Li 2012
120 mg every 6 weeks	Human	human	deep subcutaneous	3 injections, 6 weeks apart (assessed between baseline and Week 18)	Randomized trial in people · n = 46	Bajetta 2006
60-120 mg	Human	human	deep subcutaneous	Not reported	Randomized trial in people · n = 38	Trocóniz 2009
120 mg every 21 days or 180 mg every 28 days	Human	human	Not reported	24 weeks	Randomized trial in people · n = 30	Giustina 2017
30 mg once weekly	Human	human	intramuscular	3 weeks	Randomized trial in people · n = 24	Schiedermaier 2003
60, 90 or 120 mg (single administration)	Human	human	deep subcutaneous	Not reported	Randomized trial in people · n = 18	Bronstein 2005
60, 90 or 120 mg every 28 days for four administrations	Human	human	deep subcutaneous	Not reported	Randomized trial in people · n = 18	Bronstein 2005
100 microg/h infusion for 8 hours versus 800-microg bolus	Human	human	intravenous	Not reported	Randomized trial in people · n = 12	Sieber 2004
50, 100, or 200 microg/h	Human	human	intravenous	7 hours	Randomized trial in people · n = 8	Mottet 1998
100 micrograms h-t after a bolus of 100 micrograms	Human	human	intravenous	Not reported	Randomized trial in people · n = 8	Lamrani 1997
0.5 mg single dose	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 7	Falconi 2002
500 micrograms	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 4	Gancel 1994
60, 90 or 120 mg, single randomized dose	Human	human	Not reported	4 weeks	Randomized trial in people	Melmed 2010
120 mg every 4 weeks	Human	human	Not reported	Assessed at 12 weeks, within a 96-week treatment period	Randomized trial in people	Dromain 2019
120 mg every 4 weeks	Human	human	Not reported	Not reported	Randomized trial in people	Dromain 2021
120 mg	Human	human	Not reported	6 months	Randomized trial in people	Pavel 2024
120 mg single preoperative dose	Human	human	Not reported	Not reported	Trial in people without random groups · n = 98	Pillarisetty 2022
90 mg for 16 weeks, then 60, 90 or 120 mg for 32 weeks, at 28-day intervals	Human	human	Not reported	48 weeks	Trial in people without random groups · n = 63	Chanson 2008

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label describes Somatuline Depot, a prolonged-release lanreotide acetate injection. This record covers one selected label regimen.

Reported routines and cautions

What people use it for

Adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival.S1

Reported regimens

Regimens that community sources report for Lanreotide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Somatuline Depot prolonged-release lanreotide acetate injection. Adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival.Official label dosing of an approved product	deep subcutaneous injectionA healthcare provider administers the injection in the superior external quadrant of the buttock over 20 seconds. Injection sites alternate between sides.	120 mg per dose	every 4 weeks	Not stated	Single official US label source.	S1

Cautions

The label contraindicates use with a history of hypersensitivity to lanreotide.S1
The label warns about gallstones and their complications, glucose disturbances, decreased heart rate, thyroid abnormalities, and fat malabsorption.S1
For GEP-NETs, the label reports no studies in severe renal impairment or hepatic impairment.S1

Status notes

EMA lists nationally authorised lanreotide products in its 11 January 2024 document. This is not a central authorisation. Current availability in each country remains unverified.S2

Community sources

S1Somatuline Depot US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

Gaps

This record establishes one selected official label regimen, not a separate community practice regimen. It does not establish a fixed treatment duration. The full label includes other patient groups and administration conditions.

Questions and more

Ask a question about lanreotide

The answer links to every study it uses.

What does the evidence say about lanreotide?Is lanreotide tested in people?Compare with Octreotide Compare with HGH (somatotropin)

Sources

Database: PepBank data for lanreotide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about lanreotide

Lanreotide

ApprovedNot banned in sport

Also known as Somatuline Depot

What it is

Synthetic analog, 8 amino acids

Approval

Approved in the US and EU (Somatuline Depot)

In sport

Not listed as banned by WADA

Studies

110 studies with results. 109 of them gave lanreotide, with 585 results.
532 in people10 in animals43 in lab cells

Best study in people

Randomized controlled trial with 309 people (2018)

Clinical trials

85 registered: 8 active or planned, 30 with posted results

Community use

Adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival.

Dose as reported

Class

Species

Route

Duration

Design

Source

120 mg every 4 weeks

Human

human

subcutaneous

2.5 years

Randomized trial in people · n = 309

Meijer 2018

120 mg every 28 days

Human

human

Not reported

96 weeks

Randomized trial in people · n = 204

Caplin 2014

120 mg every 4 weeks

Human

human

subcutaneous

120 weeks

Randomized trial in people · n = 175

van 2019

90 mg

Human

human

Not reported

Randomized trial in people · n = 145

Gauthier 2012

120 mg monthly

Human

human

injection

three years

Randomized trial in people · n = 144

Joly 2026

Autogel 60/90/120 mg monthly

Human

human

deep subcutaneous injection

32 weeks

Randomized trial in people · n = 128

An 2020

120 mg every 4 weeks

Human

human

Not reported

16 weeks

Randomized trial in people · n = 115

Vinik 2016

30 mg PR

Human

human

intramuscular

Single first injection; outcome assessed within 72 hours

Randomized trial in people · n = 107

Gayral 2009

30 mg every 2 weeks, increased to weekly at week 8 if mean GH >2.5 microg/l

Human

human

intramuscular

4 months

Randomized trial in people · n = 98

Mao 2010

30 mg, one injection

Human

human

Not reported

10 days

Randomized trial in people · n = 80

Mariani 2012

120 mg every 28 days

Human

human

subcutaneous

Up to 1 year or progression

Randomized trial in people · n = 71

Santo 2019

120 mg every 4 weeks

Human

human

subcutaneous

16 weeks

Randomized trial in people · n = 64

Fisher 2018

30 mg every two weeks

Human

human

intramuscular

12 weeks

Randomized trial in people · n = 60

Chang 2006

120 mg every 28 days

Human

human

Not reported

24 weeks

Randomized trial in people · n = 54

van 2009

120 mg every 28 days

Human

human

Not reported

until progression or toxicity

Randomized trial in people · n = 53

Lepage 2022

120 mg every 28 days

Human

human

deep subcutaneous injection

72 weeks

Randomized trial in people · n = 44

Boertien 2024

120 mg every 4 weeks

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 40

Timmer 2024

90 mg monthly

Human

human

Not reported

Three monthly injections

Randomized trial in people · n = 24

Wauters 2019

120 mg every 28 days

Human

human

subcutaneous

120 weeks

Randomized trial in people · n = 309

Lantinga 2017

120 mg every 4 weeks

Human

human

deep subcutaneous

96 weeks

Randomized trial in people · n = 204

Buil-Bruna 2016

120 mg every 4 weeks

Human

human

subcutaneous

16 weeks

Randomized trial in people · n = 115

Fisher 2018

120 mg every 28 days

Human

human

Not reported

Randomized trial in people · n = 77

Baudin 2024

30 mg every 2 weeks, increased to 30 mg/week at week 8 if GH nadir >2.5 μg/l

Human

human

intramuscular

3 months

Randomized trial in people · n = 49

Li 2012

120 mg every 6 weeks

Human

human

deep subcutaneous

3 injections, 6 weeks apart (assessed between baseline and Week 18)

Randomized trial in people · n = 46

Bajetta 2006

60-120 mg

Human

human

deep subcutaneous

Not reported

Randomized trial in people · n = 38

Trocóniz 2009

120 mg every 21 days or 180 mg every 28 days

Human

human

Not reported

24 weeks

Randomized trial in people · n = 30

Giustina 2017

30 mg once weekly

Human

human

intramuscular

3 weeks

Randomized trial in people · n = 24

Schiedermaier 2003

60, 90 or 120 mg (single administration)

Human

human

deep subcutaneous

Not reported

Randomized trial in people · n = 18

Bronstein 2005

60, 90 or 120 mg every 28 days for four administrations

Human

human

deep subcutaneous

Not reported

Randomized trial in people · n = 18

Bronstein 2005

100 microg/h infusion for 8 hours versus 800-microg bolus

Human

human

intravenous

Not reported

Randomized trial in people · n = 12

Sieber 2004

50, 100, or 200 microg/h

Human

human

intravenous

7 hours

Randomized trial in people · n = 8

Mottet 1998

100 micrograms h-t after a bolus of 100 micrograms

Human

human

intravenous

Not reported

Randomized trial in people · n = 8

Lamrani 1997

0.5 mg single dose

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 7

Falconi 2002

500 micrograms

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 4

Gancel 1994

60, 90 or 120 mg, single randomized dose

Human

human

Not reported

4 weeks

Randomized trial in people

Melmed 2010

120 mg every 4 weeks

Human

human

Not reported

Assessed at 12 weeks, within a 96-week treatment period

Randomized trial in people

Dromain 2019

120 mg every 4 weeks

Human

human

Not reported

Randomized trial in people

Dromain 2021

120 mg

Human

human

Not reported

6 months

Randomized trial in people

Pavel 2024

120 mg single preoperative dose

Human

human

Not reported

Trial in people without random groups · n = 98

Pillarisetty 2022

90 mg for 16 weeks, then 60, 90 or 120 mg for 32 weeks, at 28-day intervals

Human

human

Not reported

48 weeks

Trial in people without random groups · n = 63

Chanson 2008

Context

Route

Amount

How often

How long

Agreement

Sources

Somatuline Depot prolonged-release lanreotide acetate injection. Adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors, to improve progression-free survival.Official label dosing of an approved product

deep subcutaneous injectionA healthcare provider administers the injection in the superior external quadrant of the buttock over 20 seconds. Injection sites alternate between sides.

120 mg per dose

every 4 weeks

Not stated

Single official US label source.

Lanreotide

Lanreotide at a glance

What is lanreotide?

The history of lanreotide

Lanreotide structure and chemistry

What lanreotide studies show

Growth hormone and growth

Cancer

Stomach and gut

Blood sugar

Daily life and fitness

Liver

Key lanreotide studies

Lanreotide clinical trials

Is lanreotide approved?

Lanreotide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about lanreotide

Related peptides

Sources

Lanreotide

Lanreotide at a glance

What is lanreotide?

The history of lanreotide

Lanreotide structure and chemistry

What lanreotide studies show

Growth hormone and growth

Cancer

Stomach and gut

Blood sugar

Daily life and fitness

Liver

Key lanreotide studies

Lanreotide clinical trials

Is lanreotide approved?

Lanreotide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about lanreotide

Related peptides

Sources